Bringing the future of brain repair for stroke, Parkinson's, and other neurological conditions to patients in Latin America, Europe and Middle East.
The company has expanded its platform with digital biomarkers, machine learning algorithms and sensor-based technologies.
Somryst is the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia.
Today, we are witnessing an upsurge in health concerns. More than half of the population has diabetes, fluctuating blood pressure, and mental health issues....
The solution, called vorvida, is launching for patients in the United States dealing with problematic alcohol use.
Near-term reductions in medical costs after prescription of reSET-O exceeded the amount needed to offset the cost of the product.
The growth comes after regulators responded to COVID-19 by loosening rules that had previously hindered the work of digital therapeutics developers.
PreferredOne will provide broad patient access and reimbursement for reSET and reSET-O for people with substance use disorder and opioid use disorder.
Digital therapeutics is a new category of medical interventions that combine patient-centric technologies with evidence-based medicine to deliver personalized care.
The pilot program will enroll 250 patients with Substance Use Disorders (SUD) and offer each patient a 12-week course of reSET therapy.
12Page 1 of 2